Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of LLP2A-Alendronate in Glucocorticoid-Induced Osteopenia
NCT03197623Phase 1Completed
- Start
- Oct 2016
- Primary completion
- Mar 2021
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteopenia, osteoporosis and osteonecrosis comparing LLP2A-ALENDRONATE with Placebo (2 arms). Primary endpoint: Dose limiting Adverse events at 4 years. Started Oct 2016; status: completed.
02
Drugs
LLP2A-alendronate
03
Conditions
osteopeniaosteoporosisosteonecrosis
Beyond the preview
Go deeper on NCT03197623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197623.